Erste Group Bank Has Positive View of Sanofi FY2026 Earnings

Sanofi (NASDAQ:SNY) – Erste Group Bank lifted their FY2026 earnings estimates for Sanofi in a research note issued on Thursday, April 2nd. Erste Group Bank analyst H. Engel now expects that the company will earn $4.92 per share for the year, up from their previous forecast of $4.91. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Erste Group Bank also issued estimates for Sanofi’s FY2027 earnings at $5.23 EPS.

Several other equities research analysts have also recently weighed in on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup began coverage on Sanofi in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $61.50.

Sanofi Trading Up 0.7%

SNY opened at $47.14 on Thursday. Sanofi has a twelve month low of $43.32 and a twelve month high of $55.73. The company has a 50-day simple moving average of $46.46 and a 200 day simple moving average of $48.01. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $114.97 billion, a price-to-earnings ratio of 13.09, a P/E/G ratio of 1.19 and a beta of 0.42.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC bought a new position in Sanofi in the 4th quarter valued at approximately $25,000. Financial Consulate Inc. bought a new position in Sanofi in the 3rd quarter valued at approximately $26,000. Measured Wealth Private Client Group LLC bought a new position in Sanofi in the 3rd quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new stake in Sanofi during the 3rd quarter valued at approximately $30,000. Finally, First Horizon Corp bought a new position in Sanofi during the 3rd quarter worth approximately $33,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.